Prostacyclin and prostaglandin E1: molecular mechanisms and therapeutic utility

Prog Hemost Thromb. 1991:10:307-37.
No abstract available

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Adenylyl Cyclases / metabolism
  • Adult
  • Alprostadil* / pharmacology
  • Alprostadil* / physiology
  • Alprostadil* / therapeutic use
  • Animals
  • Blood Platelets / drug effects
  • Blood Platelets / metabolism
  • Coronary Disease / drug therapy
  • Double-Blind Method
  • Drug Evaluation
  • Drug Tolerance
  • Ductus Arteriosus / drug effects
  • Enzyme Activation / drug effects
  • Epoprostenol* / pharmacology
  • Epoprostenol* / physiology
  • Epoprostenol* / therapeutic use
  • Extracorporeal Circulation / adverse effects
  • Heart Defects, Congenital / drug therapy
  • Heart Failure / drug therapy
  • Humans
  • Hypertension, Pulmonary / drug therapy
  • Infant
  • Infant, Newborn
  • Platelet Aggregation / drug effects
  • Raynaud Disease / drug therapy
  • Receptors, Epoprostenol
  • Receptors, Prostaglandin / metabolism
  • Receptors, Prostaglandin E
  • Renal Dialysis / adverse effects
  • Second Messenger Systems
  • Thrombocytopenia / etiology
  • Thrombocytopenia / prevention & control
  • Vascular Diseases / drug therapy

Substances

  • Receptors, Epoprostenol
  • Receptors, Prostaglandin
  • Receptors, Prostaglandin E
  • Epoprostenol
  • Adenylyl Cyclases
  • Alprostadil